Patterns of asthma-related health care resource use in children treated with montelukast or fluticasone

References

• Guilbert TW, Morgan WJ, Krawiec M, et al. The prevention of early asthma in kids study: design, rationale and methods for the Childhood Asthma Research and Education network. Control Clin Trials 2004;25:286–310
   PubMedGoogle Scholar
• Wainwright C, Isles AF, Francis PW. Asthma in children. Med J Aust 1997;167:218–23
   PubMedGoogle Scholar
• Martinez FD, Wright AL, Taussig LM, et al. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med 1995;332:133–8
   PubMed Web of Science ®Google Scholar
• National Asthma Education and Prevention Program. Expert Panel Report: guidelines for the diagnosis and management of asthma update on selected topics – 2002. J Allergy Clin Immunol 2002;110:S141–219
   PubMed Web of Science ®Google Scholar
• National Heart Lung and Blood Institute, World Health Organization. Global strategy for asthma management and prevention. Update from NHLB/WHO Workshop Report 1995. GINA.NIH Publication No. 02–3659, 2002
   Google Scholar
• National Center for Health Statistics. Asthma prevalence, health care use and mortality, 2000–2001. Available from http://www.cdc.gov/nchs/products/pubs/pubd/hestats/asthma/asthma.htm [Last accessed 7 June 2003]
   Google Scholar
• Mannino DM, Homa DM, Akinbami LJ, et al. Surveillance for asthma – United States, 1980–1999. MMWR Surveill Summ 2002;51:1–13
   PubMed Web of Science ®Google Scholar
• Donahue JG, Weiss ST, Livingston JM, et al. Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997;277:887–91
   PubMed Web of Science ®Google Scholar
• Schatz M, Nakahiro R, Crawford W, et al. Asthma quality-of-care markers using administrative data. Chest 2005;128:1968–73
   PubMed Web of Science ®Google Scholar
• Schatz M, Nakahiro R, Jones CH, et al. Asthma population management: development and validation of a practical 3-level risk stratification scheme. Am J Manag Care 2004;10:25–32
   PubMed Web of Science ®Google Scholar
• Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol 2001;107:3–8
   PubMed Web of Science ®Google Scholar
• American Lung Association Epidemiology and Statistics Unit. Trends in asthma morbidity and mortality. Research and Scientific Affairs. March 2003
   Google Scholar
• Halterman JS, Aligne CA, Auinger P, et al. Inadequate therapy for asthma among children in the United States. Pediatrics 2000;105:272–6
   PubMed Web of Science ®Google Scholar
• Williams SG, Schmidt DK, Redd SC, et al. Key clinical activities for quality asthma care. Recommendations of the National Asthma Education and Prevention Program. MMWR Recomm Rep 2003;52:1–8
   PubMedGoogle Scholar
• Ducharme FM. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. BMJ 2003;326:621
   PubMed Web of Science ®Google Scholar
• Price DB, Ben-Joseph RH, Zhang Q. Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K. Respir Med 2001;95:83–9
   PubMed Web of Science ®Google Scholar
• Bukstein DA, Henk HJ, Luskin AT. A comparison of asthma-related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy. Clin Ther 2001;23:1589–600
   Google Scholar
• Stempel DA, Mauskopf J, McLaughlin T, et al. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. Respir Med 2001;95:227–34
   PubMed Web of Science ®Google Scholar
• Allen-Ramey FC, Duong PT, Goodman DC, et al. Outcomes of patients treated with fluticasone propionate or montelukast sodium. Manag Care Interface 2003;16:30–5
   Google Scholar
• Allen-Ramey FC, Duong PT, Goodman DC, et al. Treatment effectiveness of inhaled corticosteroids and leukotriene modifiers for patients with asthma: an analysis from managed care data. Allergy Asthma Proc 2003;24:43–51
   Google Scholar
• Stoloff SW, Stempel DA, Meyer J, et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 2004;113:245–51
   PubMed Web of Science ®Google Scholar
• Orsini L, Limpa-Amara S, Crown WH, et al. Asthma hospitalization risk and costs for patients treated with fluticasone propionate vs montelukast. Ann Allergy Asthma Immunol 2004;92:523–9
   PubMed Web of Science ®Google Scholar
• Pathak DS, Davis EA, Stanford RH. Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population. Pharmacotherapy 2002;22:166–74
   Google Scholar
• Stempel DA, Meyer JW, Stanford RH, et al. One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma. J Allergy Clin Immunol 2001;107:94–8
   PubMed Web of Science ®Google Scholar
• Stempel DA, O’Donnell JC, Meyer JW. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs. J Allergy Clin Immunol 2002;109:433–9
   PubMed Web of Science ®Google Scholar
• Stempel DA, Kelly HW. Approaching value in asthma management: the need to integrate clinical and economic research with the basic science. J Allergy Clin Immunol 2002;109:S503–10
   PubMed Web of Science ®Google Scholar
• Quam L, Ellis LB, Venus P, et al. Using claims data for epidemiologic research. The concordance of claims-based criteria with the medical record and patient survey for identifying a hypertensive population. Med Care 1993;31:498–507
   Google Scholar
• Allen-Ramey FC, Duong PT, Riedel AA, et al. Observational study of the effects of montelukast and fluticasone in subjects matched at baseline. Ann Allergy Asthma Immunol 2004;93: 373–80
   PubMed Web of Science ®Google Scholar
• Parsons LS. Reducing bias in a propensity score matched-pair sample using Greedy matching techniques. Proceedings of the twenty-sixth annual SAS users group international conference, Cary, NC: SAS Institute Inc., 2001. Available from http://www2.sas.com/proceedings/sugi26/p214–26.pdf [Last accessed 19 June 2006]
   Google Scholar
• Jones C, Santanello NC, Boccuzzi SJ, et al. Adherence to prescribed treatment for asthma: evidence from pharmacy benefits data. J Asthma 2003;40:93–101
   PubMed Web of Science ®Google Scholar
• Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA 1998;279:1181–6
   PubMed Web of Science ®Google Scholar
• Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001;108:E48
   PubMed Web of Science ®Google Scholar
• Davies GM, Dasbach EJ, Santanello NC, et al. The effect of montelukast versus usual care on health care resource utilization in children aged 2 to 5 years with asthma. Clin Ther 2004;26:1895–904
   PubMed Web of Science ®Google Scholar
• Adams N, Bestall J, Malouf R, et al. Inhaled beclomethasone versus placebo for chronic asthma. Cochrane Database Syst Rev 2005;(1):CD002738
   Google Scholar
• Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998;158:1213–20
   PubMed Web of Science ®Google Scholar
• MacKenzie CA, Weinberg EG, Tabachnik E, et al. A placebo controlled trial of fluticasone propionate in asthmatic children. Eur J Pediatr 1993;152:856–60
   PubMed Web of Science ®Google Scholar
• Hoekstra MO, Grol MH, Bouman K, et al. Fluticasone propionate in children with moderate asthma. Am J Respir Crit Care Med 1996;154:1039–44
   PubMed Web of Science ®Google Scholar
• Peden DB, Berger WE, Noonan MJ, et al. Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with persistent asthma. J Allergy Clin Immunol 1998;102:32–8
   PubMed Web of Science ®Google Scholar
• Teper AM, Colom AJ, Kofman CD, et al. Effects of inhaled fluticasone propionate in children less than 2 years old with recurrent wheezing. Pediatr Pulmonol 2004;37:111–5
   PubMed Web of Science ®Google Scholar
• Zeiger RS, Bird SR, Kaplan MS, et al. Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: a randomized controlled trial. Am J Med 2005;118:649–57
   PubMed Web of Science ®Google Scholar
• Kanniess F, Richter K, Bohme S, et al. Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma. Eur Respir J 2002;20: 853–8
   PubMed Web of Science ®Google Scholar
• Busse W, Raphael GD, Galant S, et al. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol 2001;107:461–8
   PubMed Web of Science ®Google Scholar
• Ostrom NK, Decotiis BA, Lincourt WR, et al. Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. J Pediatr 2005;147:213–20
   PubMed Web of Science ®Google Scholar
• Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005;115: 233–42
   PubMed Web of Science ®Google Scholar
• Maspero JF, Duenas-Meza E, Volovitz B, et al. Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy. Curr Med Res Opin 2001;17:96–104
   PubMed Web of Science ®Google Scholar
• Bisgaard H, Zielen S, Garcia-Garcia ML, et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med 2005;171: 315–22
   Google Scholar
• Garcia Garcia ML, Wahn U, Gilles L, et al. Montelukast, compared with fluticasone, for control of asthma among 6-to 14-year old patients with mild asthma: The MOSAIC study. Pediatrics 2005;116:360–9
   PubMed Web of Science ®Google Scholar
• Bauman LJ, Wright E, Leickly FE, et al. Relationship of adherence to pediatric asthma morbidity among inner-city children. Pediatrics 2002;110:E6
   PubMed Web of Science ®Google Scholar
• Lozano P, Finkelstein JA, Hecht J, et al. Asthma medication use and disease burden in children in a primary care population. Arch Pediatr Adolesc Med 2003;157:81–8
   PubMed Web of Science ®Google Scholar
• Williams LK, Pladevall M, Xi H, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol 2004;114:1288–93
   PubMed Web of Science ®Google Scholar
• Leickly FE, Wade SL, Crain E, et al. Self-reported adherence, management behavior, and barriers to care after an emergency department visit by inner city children with asthma. Pediatrics 1998;101:E8
   PubMed Web of Science ®Google Scholar
• Gillissen A. Managing asthma in the real world. Int J Clin Pract 2004;58:592–603
   PubMed Web of Science ®Google Scholar
• Sherman J, Patel P, Hutson A, et al. Adherence to oral montelukast and inhaled fluticasone in children with persistent asthma. Pharmacotherapy 2001;21:1464–7
   PubMed Web of Science ®Google Scholar
• Kelloway JS, Wyatt RA, Adlis SA. Comparison of patients’ compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 1994;154:1349–52
   Google Scholar